Mood and Diabetes Empowerment & Improvement Training (MADE-IT)
University of California, Los Angeles (UCLA)/Drew Project EXPORT: Mood and Diabetes Empowerment & Improvement Training (MADE IT)
調査の概要
詳細な説明
The Phase I pilot recruited older Latinos from Dr. Mangione's previous study (who agreed to participate in future research) and 10 participants from a community settings. Those with low mood and poor glycemic control were offered a 12-week intervention combining cognitive behavioral therapy mood management techniques and diabetes self-care into one seamless intervention. Drs. Mangione and Miranda supervised and reviewed (through audiotapes) well-trained health educators conducting the intervention sessions. The study manuals were modified following this Phase I pilot intervention.
The final intervention manual was tested in a randomized trial in Phase II, compared the Mood and Diabetes Empowerment and Improvement Training intervention with enhanced care as usual (providing participants with a letter regarding their mood and hemoglobin (Hb)A1c with recommendations for improving care for their provider). The target population was low-income Latinos with depression and poor glycemic control. Both mood and diabetes outcomes are evaluated.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
California
-
Los Angeles、California、アメリカ、90095
- UCLA Psychr & Biobehav Sci
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Latino men and women age 50 and older
- Must speak English or Spanish
- Hb A1c greater than or equal to 8%
- Currently not taking medication for depression
- A score of 5 or greater on the Geriatric Depression Scale (GDS)
Exclusion Criteria:
- Persons who are legally blind, dialysis dependent, diagnosed with dementia, and/or with hemiparesis from a cerebral vascular accident
- Do not have sufficient hearing or cognitive function
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
介入なし:Wait-listed Control Group
Participants in the Wait-listed Control Group will receive augmented access and communication with a primary care provider.
The augmentation would consist of providing the participant with a letter to be shared with their primary care doctor indicating their Hb A1c level and depression score at the time of eligibility screening.
The research team will also attach a list of local mental health service providers to the letter.
The participants randomized to the wait-listed control group will also be offered access to the intervention after the trial is completed in the event that the randomized controlled trial (RCT) has significant results.
|
|
|
実験的:Empowerment and CBT Classes
Participants will attend weekly 2-hour group Empowerment and CBT classes for 12 weeks led by two trained health educators.
Participants will learn cognitive behavioral therapy (CBT) techniques to manage their mood.
After CBT, participants will learn a diabetes education format that is grounded in empowerment theory that employs group problem solving, individualized goal setting, and personal behavioral change "experiments" designed to help patients set priorities and to become better self-managers of both diabetes and their mood.
As part of the intervention activities, group members will be advised to monitor their blood sugar levels, blood pressure, and mood on a daily basis.
|
Participants randomized to the intervention arm will receive a manual with 3 CBT modules and 1 Diabetes Empowerment module.
CBT Module 1 covers "Understanding Depression and Diabetes", Module 2 "How Thoughts Affect Your Mood and Diabetes Care", Module 3 "How Activities Affect Your Mood and Diabetes Care".
The Diabetes Empowerment Module covers topics including the following: food, exercise, medicine, diabetes and your health, social support, communication skills, and community resources.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change From Baseline in Hemoglobin A1c at 6 Months
時間枠:Baseline and 6 months
|
Hemoglobin A1c (HbA1c) measures glycemic control over the past three months.
HbA1c was measured by a blood draw and laboratory test.
|
Baseline and 6 months
|
|
Change From Baseline in Depression Measures at 6 Months
時間枠:Baseline and 6 months
|
The Geriatric Depression Scale (GDS) measures depression in older adults. The short form we used consists of 15 yes or no questions. The scale range is 0 to 15, where higher scores indicate greater severity of depression. The Patient Health Questionnaire-9 (PHQ-9) measures depression in patients. The questionnaire consists of 9 questions where patients self report how frequently they have depression symptoms over the past two weeks. The scale ranges is 0 to 27 where higher scores indicate greater severity of depression. |
Baseline and 6 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change From Baseline in Blood Pressure at 6 Months
時間枠:Baseline and 6 months
|
Baseline and 6 months
|
|
|
Change From Baseline in Low Density Lipoprotein-C at 6 Months
時間枠:Baseline and 6 months
|
Baseline and 6 months
|
|
|
Change From Baseline in EQ-5D at 6 Months
時間枠:Baseline and 6 months
|
The EQ-5D measures general quality of life. The index score is based on 5 questions about mobility, self-care, pain, usual activities, and psychological status. The EuroQol Group provides a U.S. preference-weighted algorithm to calculate the index scores. A score of 1 indicates no problems while a score of -0.11 indicates severe problems. The scale score is based on a visual analog of a thermostat, where 0 represents worst imaginable health and 100 represents best imaginable health. Patients mark a tick for where they feel their health is on that scale. |
Baseline and 6 months
|
|
Change From Baseline in Yale Physical Activity Scale - Index Summary Score at 6 Months
時間枠:Baseline and 6 months
|
The Yale Physical Activity Scale measures physical function and activities of daily living.
Five activity indices (vigorous activity, leisurely walking, moving, standing and sitting) are calculated by multiplying the frequency of activity with the duration and a weighted factor.
The 5 indices are then summed to create an index summary.
Higher scores indicate more activity.
The minimum and maximum scores are 0 and 142.
|
Baseline and 6 months
|
|
Change From Baseline in Self-Efficacy (Diabetes Empowerment Scale) at 6 Months
時間枠:Baseline and 6 months
|
The Diabetes Empowerment Scale Short Form (DES-SF) measures diabetes-related psychosocial self-efficacy.
The questionnaire presents 8 statements on self-efficacy where participants rate how strongly they agree.
The answers are summed to create a score where higher scores indicate more empowerment.
The score range is 0 to 8.
|
Baseline and 6 months
|
協力者と研究者
捜査官
- 主任研究者:Jeanne Miranda, PhD、UCLA Psychr & Biobehav Sci
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。